Authors
Latest:
Retrospective Radiotherapy in IBD Data May Warrant Prospective ResearchRetrospective study data show that patients with inflammatory bowel disease may not require modification of standard radiotherapy for pelvic malignancies.
Latest:
Nadofaragene Firadenovec Results in uMRD-Negative Status in NMBICuMRD-negative status linked to recurrence-free outcomes with nadofaragene firadenovec in NMIBC
Latest:
The Future of Immunotherapy in Low-Grade Serous Ovarian Cancer TreatmentThe panel explains how low-grade serous ovarian cancer differs from high-grade, and if an immunotherapy approach is appropriate for treatment.
Latest:
Future Therapies for ALK+ Metastatic NSCLCDr. Kim shares her insights on new investigational therapies for metastatic ALK+ NSCLC that she's particularly excited about.
Latest:
Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous CarcinosarcomaThis study presents a case of a man, aged 56 years, found to have a 26-mm exophytic lesion on the vertex scalp identified to contain a distinct population of basal cell carcinoma as well as another population of spindled cells representing a poorly differentiated sarcomatous component.
Latest:
Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous SystemAnaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.
Latest:
Cross Q&A: Role of Belantamab Mafodotin in MMThe panel discusses the efficacy of belantamab mafoditin and where the treatment fits in the multiple myeloma treatment landscape.
Latest:
R/R MM: Bispecifics in R/R MM: Key TakeawaysPanelists discuss how to manage talquetamab-associated adverse events, such as skin toxicities and dysgeusia, sharing their clinical experience with toxicity timing, frequency, and key strategies for fellow oncologists implementing bispecific antibodies in relapsed/refractory multiple myeloma.
Latest:
Future Perspectives: What’s Next in NDMM?Panelists discuss how the treatment landscape for patients with transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM) is expected to evolve, with considerations for optimizing therapeutic approaches based on emerging data from novel drug combinations and treatment strategies.
Latest:
Best Treatment Selection in Clear-Cell RCCMedical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.
Latest:
ONCOLOGY® Looks to Conference Agendas for Current Trends"Witnessing the resiliency of the oncology community in the face of challenges to both patients and their providers builds momentum in the community and is sure to lead to better outcomes going forward."
Latest:
Radiopharmaceutical Agent Shows Efficacy, Tolerability in SSTR2+ NETsBrandon R. Mancini, MD, MBA, FACRO, discussed results from a phase 1/2a trial that evaluated [212Pb]VMT-α-NET in patients with advanced NETs.
Latest:
Douglas Blayney, MD, on Reducing the Incidence of CIN with Plinabulin Plus PegfilgrastimPlinabulin in combination with pegfilgrastim reduced the incidence of chemotherapy-induced neutropenia, compared with pegfilgrastim alone, in patients with breast cancer undergoing chemotherapy with docetaxel, doxorubicin, and cyclophosphamide.
Latest:
Adverse Effects Associated with SBRT in Patients With HCCThe panel discusses adverse effects associated with stereotactic body radiation therapy, and the Oncology Brothers provide a recap of the entire discussion.
Latest:
Evaluation and Management of Testicular Cancer After Late RelapseThe clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.
Latest:
Solange Peters, MD, PhD, Reviews Evolving Treatment Trends in Lung Cancer“Be courageous: Your work will be recognized, and everything is about [the] work in the end.”
Latest:
Deciding Which Cancer-Related Fatigue Assessment Tool to Use Just Got Much EasierLisa Sprod, PhD, MPH, provides perspective on a cancer-related fatigue assessment tools.
